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S276 Poster Session IBreakthrough fungal infections were observed in 4 (6%) and 11
(15%) patients in the L-ampho B and the caspofungin groups, re-
spectively (p 5 0.2). Of all, 13 were due to Aspergillus spp while 1
C. neoformans CNS infection and 1 B. capitatus fungemia were ob-
served in patients receiving caspofungin. Nine additional patients
had a baseline fungal infection (4 in the L-ampho B group and 5 in
the caspofungin group) and none of them had successful treatment.
Resolution of fever during neutropenia was seen in 40 (66%) and 41
(56%) of patients in the L-ampho B and the caspofungin groups,
respectively (p5 0.17). There was a trend towards higher premature
discontinuation of therapy due to lack of efficacy or toxicity in the
caspofungin group (27% vs 13%, p 5 0.057). However, more pa-
tients survived at least 7 days after completion of therapy in the cas-
pofungin group (92% vs 75%, p 5 0.007). The overall success rate
defined as the fulfilment of all 5 composite end points was achieved
in 28 (46%) and 24 (33%) patients in the L-ampho B and the caspo-
fungin groups, respectively (p 5 0.16).
L-ampho B and caspofungin were both effective when given as
empirical antifungal therapy for the treatment of PFN in patients un-
dergoing allogeneic SCT. Differences between L-ampho B and cas-
pofungin in overall success assessed by the 5-component end point
were not statistically significant.336
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Background:The number of Hematopoietic StemCell Transplants
(HSCT) has increased over the past 25 years with higher rates of
success and a large number of long-term survivors. Patients who un-
dergo either an autologous or allogeneic HSCT experience pro-
found immunosuppression from the conditioning regimen causing
them to lose the immunity gained from previous vaccinations. Ac-
knowledging the need for consistency among practices, the Centers
for Disease Control and Prevention, Infectious Disease Society of
America, and the American Society of Blood and Marrow Trans-
plantation published guidelines regarding re-immunization post
HSCT in 2000.
Purpose: The purpose of this study was to assess patient adherence
to re-immunization guidelines after HSCT. Completeness, timeli-
ness, factors influencing adherence and parental identification of
barriers to re-immunization were also examined.
Methods: Patients who received anHSCTbetween 01/01/2001 and
12/31/2007 and were alive at time of recruitment were eligible for
enrollment. Parents of eligible patients were contacted to participate
in a phone survey assessing perceptions of and barriers to re-immu-
nization. Vaccination data was abstracted using theGeorgia Registry
of Immunization Transactions and Services (GRITS), a state-wide
mandatory reporting database for Georgia.
Results: Of the 271 patients transplanted during the designated
time period, 98 met eligibility criteria and 58 completed the phone
survey. Of the phone survey participants, 90% (N 5 58) reported
being told their child would need to be re-immunized post HSCT
and 89% (N 5 57) reported their child being up to date on immu-
nizations to the best of their knowledge. Data in GRITS, however,
showed that only 9% (N 5 98) had completed all doses of 6 of the
recommended vaccines (Hep B, HiB, MMR, Polio, PPV, DTaP/
Td). On average patients who had received at least one post-
HSCT vaccination completed 60% of the recommended doses
(N 5 87). Patients who received allogeneic transplants averaged
63% (N 5 56) complete while patients who received autologous
averaged 54% (N 5 31) complete. The guidelines recommend pa-
tients begin re-immunization 365 days post HSCT. The average
time to first immunization post HSCT was 639 days (median
512 days, range 195 – 2728 days).
Conclusion: Parents perceived their children to be more up to date
with their re-immunizations than was found in GRITS data. Further
education is needed for both parents and healthcare providers caring
for these patients.337
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Backgrounds: Although drug interaction between calcineurin in-
hibitors and voriconazole has been recognized, the interaction has
not been fully evaluated in hematopoietic stem cell transplantation
(HSCT) recipients. We have previously shown a notably wide vari-
ability in the effect of voriconazole administration on the concentra-
tion of calcineurin inhibitors in HSCT recipients, in whom
voriconazole and calcineurin inhibitors were administered orally or
intravenously (Bone Marrow Transplant 2009;44:371). In the pres-
ent study, the drug interaction between voriconazole and tacrolimus
was evaluated in HSCT recipients, when both were orally adminis-
tered. In addition, bioavailability of voriconazole was evaluated
and its association with the drug interaction was quantitatively
assessed.
Patients & Methods: Twenty-two recipients of allogeneic HSCT
who had already been on a steady dose of orally administered tacro-
limus, and were started on voriconazole (orally 200 mg per body ev-
ery 12 h) for the treatment or prophylaxis of fungal infection were
evaluated. Conditioning were myeloablative in 12 patients, and re-
duced-intensity in 8 patients. The concentration/dose (C/D; (ng/
ml)/(mg/kg)) ratio of calcineurin inhibitors was calculated before
and 7–10 days after initiating voriconazole administration. The C/
D ratios before and after voriconazole administration were com-
pared, and increased rate (%) was calculated. The plasma level of
voriconazole was measured by high-performance liquid chromatog-
raphy.
Results:Themedian C/D ratio of tacrolimus significantly increased
to 531.1 (ng/ml)/(mg/kg) (range, 127.8-759.2) after initiating vori-
conazole administration as compared with that before (169.6 (range,
128.6-541.3): P\0.001). Median increased rate of C/D ratios were
196.8% with a range of -32.0% to 685.7%. The plasma level of vor-
iconazole on the day of evaluating C/D ratio was 2.3961.67 mg/ml,
which was lower than 1.0 mg/ml in 4 patients and higher than 4.0
mg/ml in 3 patients. The increased rate of C/D ratio of tacrolimus
did not correlate with the plasma level of voriconazole (r 5 -0.05,
P 5 0.838).
Conclusion: Orally administered voriconazole demonstrates
a significant interaction with orally administered tacrolimus with
a wide interindividual variability in the magnitude. A wide interindi-
vidual variability could not be explained by the difference in the bio-
availability of voriconazole, and other mechanisms such as p-gp
should be investigated.338
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Parainfluenza virus (PIV) infections are common after allogeneic
SCT and can cause severe morbidity, yet there is no effective treat-
ment. DAS181 is an investigational antiviral medication which is ac-
tive in vitro and in vivo against PIV. It is a recombinant sialidase
protein which removes sialic acid residues. Binding to these residues
is the initial step in PIV infection. We report the first treatment of
PIV3 infection with DAS181 in a SCT patient. A 63 year-old female
with AMLunderwent a second SCT after primary graft failure. Con-
ditioning included fludarabine and alemtuzumab, with tacrolimus as
GVHD prophylaxis. After engraftment, her course was complicated
by grade III skin GVHD which was treated with steroids and myco-
phenolate mofetil. Three months after her second SCT, she devel-
oped nasal congestion and cough and was found to have PIV3
infection. She was treated with bronchodilators and IVIG. There
was no evidence of superinfection. She was admitted 6 weeks later
for pancytopenia and worsening respiratory status thought to be
from progressive PIV3 infection. Given her worsening status, we ob-
tained an emergency IND from the FDA to administer DAS181.
